logo
logo

Curium acquires Monrol to boost Lu-177 capacity

Mar 28, 2025•4 months ago

Acquiring Company

Curium Pharma

Acquired Company

Monrol

ParisIstanbulBiotechnologyHealth CareManufacturingBiotechnologyHealth Care

Description

Curium Pharma has completed the acquisition of Eczacıbaşı-Monrol Nuclear Products Co. This acquisition enhances Curium's manufacturing capacity for Lutetium-177, expands its geographical footprint, and adds significant R&D capabilities. The deal will help meet rising global demand for isotopes and secure the supply of Curium’s new drug candidates.

Company Information

Company

Curium Pharma

Location

Paris, Texas, United States

About

Curium is the global leader in nuclear medicine, providing life-changing diagnostics and treatment to patients all over the world. We develop, manufacture and distribute world-class radiopharmaceutical products with a renewed focus on cancer, exploring untapped potential for new innovation.

Related People

Sign in to view contact details

Sign in to view contact details

M&A Insights

Based on deal data
Integration timeline
70% of M&A integrations take 12-24 months to complete
Tech stack consolidation
83% of merged companies consolidate technology vendors within first year
Post-acquisition investment
Companies increase IT spending by 23% on average after acquisitions
Success factor
M&A deals with strong technology integration plans are 2.5x more likely to succeed